Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00117507|
Recruitment Status : Completed
First Posted : July 7, 2005
Last Update Posted : March 1, 2017
Thirty patients will be enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic syndrome (MDS) patients with iron overload. Patients enrolled in this study will have low or intermediate (INT-1) risk MDS per International Prognostic Scoring System (IPSS) criteria. All patients will initiate treatment with 20mg/kg/day deferasirox.
Deferasirox will be administered orally once per day for 12 months.
|Condition or disease||Intervention/treatment||Phase|
|Myelodysplastic Syndromes Iron Overload||Drug: deferasirox||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-Risk and INT-1 Myelodysplastic Patients|
|Study Start Date :||April 2005|
|Primary Completion Date :||January 2008|
|Study Completion Date :||January 2008|
Experimental: 20mg/kg/day deferasirox
Deferasirox will be administered orally once per day for 12 months. Surrogate marker findings, including serum ferritin, and LIC in the context of the study results will be monitored on a regular basis for any indications of clinically important over- or under-chelation.
deferasirox 20 mg/kg/day taken over one year.Deferasirox should be taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets should be dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
- Safety and tolerability in myelodysplastic syndrome (MDS) patients [ Time Frame: 12 months ]
- Efficacy based on serum ferritin and Liver iron concentration (LIC) [ Time Frame: through out the study ]
- Changes in liver iron concentration (LIC) [ Time Frame: through out the study ]
- Pharmacokinetics (PK) in MDS patients [ Time Frame: through out the study ]
- Non-transferrin bound iron (NTBI) & iron metabolism parameters [ Time Frame: through out the study ]
- Iron metabolism parameters [ Time Frame: through out the study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00117507
|United States, California|
|Stanford University Medical Center|
|Stanford, California, United States, 94305-5821|
|United States, Michigan|
|Karmanos Cancer Center|
|Detroit, Michigan, United States, 48201|
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030-4009|
|Study Director:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|